BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12819960)

  • 1. Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.
    Xiang W; Wimberger P; Dreier T; Diebold J; Mayr D; Baeuerle PA; Kimmig R
    J Cancer Res Clin Oncol; 2003 Jun; 129(6):341-8. PubMed ID: 12819960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
    Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
    Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.
    Prang N; Preithner S; Brischwein K; Göster P; Wöppel A; Müller J; Steiger C; Peters M; Baeuerle PA; da Silva AJ
    Br J Cancer; 2005 Jan; 92(2):342-9. PubMed ID: 15655555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
    Naundorf S; Preithner S; Mayer P; Lippold S; Wolf A; Hanakam F; Fichtner I; Kufer P; Raum T; Riethmüller G; Baeuerle PA; Dreier T
    Int J Cancer; 2002 Jul; 100(1):101-10. PubMed ID: 12115595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
    Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
    Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
    El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.
    Kim JH; Herlyn D; Wong KK; Park DC; Schorge JO; Lu KH; Skates SJ; Cramer DW; Berkowitz RS; Mok SC
    Clin Cancer Res; 2003 Oct; 9(13):4782-91. PubMed ID: 14581349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
    Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
    Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific targeting of Ep-CAM in various carcinomas by novel monoclonal antibodies.
    Sithambaram D; Palanivelu S; Subramanian K; Sahoo S; Verma RS
    Hybridoma (Larchmt); 2011 Dec; 30(6):511-8. PubMed ID: 22149275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
    Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P
    J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
    Thurm H; Ebel S; Kentenich C; Hemsen A; Riethdorf S; Coith C; Wallwiener D; Braun S; Oberhoff C; Jänicke F; Pantel K
    Clin Cancer Res; 2003 Jul; 9(7):2598-604. PubMed ID: 12855636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
    Spizzo G; Went P; Dirnhofer S; Obrist P; Moch H; Baeuerle PA; Mueller-Holzner E; Marth C; Gastl G; Zeimet AG
    Gynecol Oncol; 2006 Nov; 103(2):483-8. PubMed ID: 16678891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.
    Mosolits S; Markovic K; Frödin JE; Virving L; Magnusson CG; Steinitz M; Fagerberg J; Mellstedt H
    Clin Cancer Res; 2004 Aug; 10(16):5391-402. PubMed ID: 15328177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
    Riesenberg R; Buchner A; Pohla H; Lindhofer H
    J Histochem Cytochem; 2001 Jul; 49(7):911-7. PubMed ID: 11410615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.
    Nagorsen D; Keilholz U; Rivoltini L; Schmittel A; Letsch A; Asemissen AM; Berger G; Buhr HJ; Thiel E; Scheibenbogen C
    Cancer Res; 2000 Sep; 60(17):4850-4. PubMed ID: 10987297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.